 |
26 Diseases |  |
7 Trials |
|
7 Trials |  |
4331 News |  |
| «12345678910111213...5051» |
- || icosapent ethyl / Generic mfg.
Doctors aren't pushing VASCEPA hard enough, @DLBHATTMD (Twitter) - Jan 17, 2023
- || icosapent ethyl / Generic mfg.
Repeat after me "Vascepa ". (Twitter) - Jan 16, 2023
- || icosapent ethyl / Generic mfg.
Yes Vascepa, still in trials I assume. Its suppose to help in single dose. (Twitter) - Jan 13, 2023
- || icosapent ethyl / Generic mfg.
Icosapent ethyl (prescription drug Vascepa) was shown to drastically reduce low attenuation (vulnerable) plaque within 18 months when combined with a statin in the EVAPORATE trial by @BudoffMd https://t.co/fp6jjrzICO (Twitter) - Jan 13, 2023
- || icosapent ethyl / Generic mfg.
Review, Journal: Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review. (Pubmed Central) - Jan 13, 2023
All other trials and observational studies have supported the role of Vascepa in hypertriglyceridemia and CV risk reduction. In conclusion, the use of IPE has been shown to significantly reduce triglyceride levels and reduce CV risks in patients receiving optimal statin therapy.
- | icosapent ethyl / Generic mfg.
Journal: Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease. (Pubmed Central) - Jan 12, 2023
P=N/A
A large proportion of high-intensity, statin-treated, high-risk patients with ASCVD and of self-reported SA ethnicity are eligible for IPE. These data have important translational implications for SAs who are at a disproportionately higher risk of CV morbidity and mortality.
- || icosapent ethyl / Generic mfg.
Morale of the story: take Vascepa 😁 (Twitter) - Jan 7, 2023
- icosapent ethyl / Generic mfg.
COMPARING THE EFFECTS OF PHARMACEUTICAL GRADE MINERAL OIL, CORN OIL, EICOSAPENTAENOIC ACID (EPA) AND DOCOSAHEXAENOIC ACID (DHA) IN A MODEL OF ATHEROSCLEROSIS IN VITRO (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_7164;
The distinct antioxidant actions of EPA may contribute to reduced events in CV outcome trials using IPE compared to DHA containing formulations. The placebo oils did not influence lipoprotein oxidation even at supra-pharmacologic levels.
- icosapent ethyl / Generic mfg.
MANAGEMENT OF ELEVATED TRIGLYCERIDE LEVELS IN PATIENTS FOLLOWING ACUTE CORONARY SYNDROME: REAL-WORLD RESULTS FROM A LARGE INTEGRATED HEALTHCARE SYSTEM (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_5793;
This study demonstrates no change in TG levels despite 95.9% utilization rate of high-dose statin therapy in a real-world post-ACS population. There appears to be a need for a more comprehensive management strategy to reduce residual cardiovascular risk in post-ACS patients with elevated triglycerides.
- icosapent ethyl / Generic mfg.
BENEFITS OF ICOSAPENT ETHYL IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME (ACS): REDUCE-IT ACS (Room 219; [In-Person]; [ACC Anywhere]) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4028;
There appears to be a need for a more comprehensive management strategy to reduce residual cardiovascular risk in post-ACS patients with elevated triglycerides. IPE significantly reduced the risk of first and total ischemic events in patients with recent ACS without increased bleeding, supporting early initiation of IPE after ACS.
- |||| icosapent ethyl / Generic mfg.
Clinical: Potential for Residual Cardiovascular Risk Reduction: Eligibility for Icosapent Ethyl in the VERTIS CV Population with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease by Baim Faculty @cpcannon https://t.co/y6mp4EjuIG (Twitter) - Jan 4, 2023
- || icosapent ethyl / Generic mfg.
@MarkBrady2014 @DLBHATTMD @Amarincorp #vazkepa #vacespa (Twitter) - Jan 4, 2023
- ||| icosapent ethyl / Generic mfg., omega-3 ethylester concentrate / Generic mfg.
Clinical: Vascepa does not increase LDL. That was their marketing prior to REDUCE-IT study. Lovaza increases LDL. Feel bad for your patients. (Twitter) - Dec 31, 2022
- || icosapent ethyl / Generic mfg.
By the way, Vascepa also shows significant coronary plaque regression as seen in EVAPORATE and CHERRY studies (Twitter) - Dec 31, 2022
- ||| icosapent ethyl / Generic mfg.
Relative risk: Interesting that you can look at a chart with such wonderful relative risk reduction on top of statins and not see the benefit of pursuing both LDL reduction while prescribing Vascepa as well. It is not about money, it’s about preventing strokes, MI etc. (Twitter) - Dec 31, 2022
- ||| icosapent ethyl / Generic mfg.
Almost! You almost got it right. Lowering LDL-c is the preferred strategy, but not the only pathway. BTW in RCT's involving OMG-3's contrary to your assertion, VASCEPA actually lowered LDL-c by 5% while others, (as you said), raised LDL-c. (Twitter) - Dec 31, 2022
- || icosapent ethyl / Generic mfg.
Clinical, Review, Journal: Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. (Pubmed Central) - Dec 30, 2022
In particular, CV trials using icosapent ethyl (IPE), a highly purified ethyl ester of EPA, reproducibly reduced CV events and progression of atherosclerosis compared with mixed EPA/DHA treatments...These effects include altered platelet function, inflammation, cholesterol distribution, and endothelial dysfunction. Elucidating such mechanisms of vascular protection for EPA may lead to new interventions for atherosclerosis, a disease that continues to expand worldwide.
- |||| ezetimibe / Generic mfg., icosapent ethyl / Generic mfg., Repatha (evolocumab) / Amgen, Astellas
Clinical: My CVD patients LDL-C <1.0mmol/L (<20mg/dL) on rsouvastatin + ezetimibe or Repatha (PCSK9 inhibitor) and show significant coronary plaque regression and are asymptomatic. By the way fish oil incl. Vascepa lower triglycerides & elevate LDL-C! $$ & materialistic spin are your gods (Twitter) - Dec 30, 2022
- || icosapent ethyl / Generic mfg., fenofibrate / Generic mfg., omega-3 ethylester concentrate / Generic mfg.
He doesn’t even believe in the Reduce it trial or the benefits of Vascepa from @Amarincorp. I bet he prescribes Lovaza and Fenofibrates to prevent CVD and HTG. 🤡 (Twitter) - Dec 29, 2022
- |||| icosapent ethyl / Generic mfg.
Clinical: Look at this mental patient! Looks like his TDS (Trump Derangement Syndrome) has progressed into a severe case of VDS (Vascepa Derangement Syndrome)👇 (Twitter) - Dec 29, 2022
- || icosapent ethyl / Generic mfg.
Pretty sure he is an investor in $AMRN ******** BECAUSE ******** of how great Vascepa is. (Twitter) - Dec 29, 2022
- || icosapent ethyl / Generic mfg., Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Stop it Steven it is obvious you are still jaded over the failed Epanova Strength study. $AMRN #Vascepa @Amarincorp (Twitter) - Dec 29, 2022
- || icosapent ethyl / Generic mfg.
Clever and spot on! $AMRN@VAZKEPA/@VASCEPA (Twitter) - Dec 29, 2022
- |||| icosapent ethyl / Generic mfg.
#EPA #VASCEPA #EBM $AMRN @DLBHATTMD @SABOURETCardio @VietHeartPA Pick your Cardiovascular Condition or Event and VASCEPA (IPE) can REDUCE-IT! (Twitter) - Dec 29, 2022
- | icosapent (MND-2119) / Mochida, Amarin
Preclinical, Journal: Icosapent ethyl alleviates acetic acid-induced ulcerative colitis via modulation of SIRT1 signaling pathway in rats. (Pubmed Central) - Dec 28, 2022
Icosapent effects were antagonized by EX527. Icosapent alleviated acetic acid-induced colitis via its anti-inflammatory, antioxidant, and anti-apoptotic effects mediated in part by SIRT1 pathway activation.
- ||| icosapent ethyl / Generic mfg.
👋 Cleveland Clinic Could one of you astute folks please pass this link to Steven Nissen, as he's been having comprehension problems with VASCEPA? @ClevelandClinic @ClevClinicHeart @CCFcards @CleClinicNews @DLBHATTMD @VietHeartPA @BudoffMd @mmillermd1 https://t.co/QyTstbxWYb (Twitter) - Dec 27, 2022
- ||| icosapent ethyl / Generic mfg.
Gold standard: Your brand only contains 355 mg of EPA, plus 235 mg of DHA. That’s 3:2 ratio—not good for our purposes. The most pertinent studies I cited used from 2000 to 4000 mg EPA and no DHA. Completely different, so it isn’t surprising that supplement didn’t help. Vascepa = gold standard (Twitter) - Dec 19, 2022
- || Juxtapid (lomitapide) / Amryt, Novelion, Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
Review, Journal: A stepwise approach to prescribing novel lipid-lowering medications. (Pubmed Central) - Dec 17, 2022
Several new lipid lowering medications have received approval by regulatory agencies in the past decade including proprotein convertase subtilisin/kexin type 9 modulators, ATP-citrate lyase inhibitors, angiopoietin-like 3 inhibitors, lomitapide, and icosapent ethyl...This information can help the clinicians to prescribing these novel lipid lowering medications to achieve treatment goals and reduce the risk of atherosclerotic cardiovascular disease. The aim is to shift the paradigm for high-intensity statins from watch and wait to initial combination therapy for high-risk patients.
- ||| icosapent ethyl / Generic mfg., omega-3 ethylester concentrate / Generic mfg.
Clinical: Doctors are wage employees doing as their told. Until the standard of care tells them to prescribe Vascepa instead of Fibrates and Lovaza they will keep doing as their told. Order followers. I bet they tell their patients to wear masks and get the jabs. (Twitter) - Dec 14, 2022
- |||| icosapent ethyl / Generic mfg., omega-3 ethylester concentrate / Generic mfg.
#VASCEPA @AmarinCorp @DLBHATTMD @Drlipid @VietHeartPA @BudoffMD @ErinMichos @mmillermd1 @PrakritiGaba @PamTaubMD With the new emphasis for “Lower LDL-c the Better”, Why are US cardiologists, physicians and Practitioners still writing 65,000 Lovaza/generic Lovaza Scripts each wk? (Twitter) - Dec 14, 2022
- icosapent ethyl / Generic mfg.
IMPACT OF ICOSAPENT ETHYL ON ALZHEIMERS DISEASE BIOMARKERS IN PRECLINICAL ADULTS: BRAIN AMYLOID AND VASCULAR EFFECTS OF EIOSCAPENTAEOIC ACID (BRAVE-EPA) STUDY DESIGN AND BASELINE CHARACTERISTICS. () - Dec 9, 2022 - Abstract #CTAD2022CTAD_371;
These data support the feasibility of recruiting cognitively unimpaired Veterans into a randomized, placebo-controlled clinical trial assessing the impact of IPE on MRI, CSF, and cognitive AD biomarkers. Trial data collection is ongoing and will be completed in September 2023.
- || icosapent ethyl / Generic mfg.
So, how about this combo for statin intolerant: #BA + #VASCEPA? @DLBHATTMD @mmillermd1 @BudoffMd @VietHeartPA (Twitter) - Dec 9, 2022
- || icosapent ethyl / Generic mfg.
Dr Bhatt, Can you please advise what it would take (money, time, experts, etc) to run such studies? I know dozens of people whose coverage of Vascepa is being dropped, but they aren't confident in making the switch to Generic until testing confirms their bioequivalence. T.I.A. (Twitter) - Dec 8, 2022
- |||| icosapent ethyl / Generic mfg.
Clinical, Adverse events: Use of icosapent ethyl, a highly purified EPA, may be associated with a reduction in risk of adverse cardiovascular events in patients with chronic CAD who were also being treated with statins. @DLBHATTMD of @MountSinaiHeart discusses the study: https://t.co/7VY3EmNpdh (Twitter) - Dec 8, 2022
- |||| icosapent ethyl / Generic mfg.
NICE: It is my pleasure to announce the updated @NICEComms endorsed @AACinnovation @NHSEngland National Lipid Management Pathway. It now includes icosapent ethyl. https://t.co/ta51IQ7gNI (Twitter) - Dec 8, 2022
- |||| icosapent ethyl / Generic mfg.
Clinical: When will you discuss Vascepa being effective with long covid patients? @amarin$AMRN@VASCEPA @DLBHATTMD (Twitter) - Dec 6, 2022
- || icosapent ethyl / Generic mfg.
Yeah and FDA literally had an SPA with the company when conducting the study. Maybe you should ask the fDA why you think they messed up in coming up with the study? #vascepa (Twitter) - Dec 5, 2022
- || icosapent ethyl / Generic mfg.
More specifically, your CVD insureds that have a prescription for #Vascepa which has a CVD indication that you are dropping. Overage for ND replacing it with a generic version that has not been approved for CVD. Why and how can you do this to these parties? (Twitter) - Dec 5, 2022
- |||| icosapent ethyl / Generic mfg.
Clinical: 👋 @fepblue You dropped coverage of VASCEPA for your 5,500,000 members while CVD remains the top killer in 🇺🇸 REDUCE-IT trial, featuring VASCEPA: ➡️ PLACEBO: 4090 patients, 1546 events ➡️ VASCEPA: 4089 patients, 1076 events 🚨 470 fewer events in the VASCEPA arm @DLBHATTMD👇 https://t.co/G8yhsxciNS (Twitter) - Dec 4, 2022
- |||| icosapent ethyl / Generic mfg.
What I am looking forward to is for @fepblue to cover VASCEPA in 2023, as they have 2014-2022. Unfortunately, they chose not to cover VASCEPA in 2023, despite VASCEPA reducing cardiovascular events by 33%. Here is the letter they sent out 👇 @FDACommissioner @DLBHATTMD (Twitter) - Dec 3, 2022
- ||| icosapent ethyl / Generic mfg.
Vascepa is protected from oxidation by patented capsule. Generics use toxic preservatives in an attempt to prevent oxidation (look at the ingredients) One has been studied for CVD RRR, one has not been studied and is only approved for hypertriglyceridemia (Twitter) - Dec 2, 2022
- ||||| icosapent ethyl / Generic mfg.
Clinical: Icosapent ethyl in patients with CAD and high triglycerides? Unlike other omega-3’s (EPA+DHA) with prior trials showing negative results, @DLBHATTMD et al showed icosapent ethyl (pure EPA) to reduce CV events and mortality in this landmark study. REDUCE-IT Trial, NEJM 2019 ♥️ (Twitter) - Dec 2, 2022
- ||| icosapent ethyl / Generic mfg.
Clinical: This is dangerous. @fepblue should update their 2023 and cover Vascepa (which reduces CVD by 25%, see link) or stop trying to mislead their patients. https://t.co/1t6CbuV8sK @American_Heart @ACCinTouch @DLBHATTMD @VietHeartPA @BudoffMd @mmillermd1 @Amarincorp @SABOURETCardio (Twitter) - Dec 2, 2022
- |||| icosapent ethyl / Generic mfg.
Clinical: What do you mean "could mean"?! No need to guess or speculate or pretend or imagine. Here is the *actual* REDUCE-IT data: ➡️ 1546 events in placebo arm vs 1076 events in Vascepa arm ***470 CV EVENTS PREVENTED*** You're welcome, again. (Twitter) - Dec 2, 2022
- ||| icosapent ethyl / Generic mfg.
Clinical: Is this why the REDUCE-IT trial showed a 25%+ reduction in CV events for the Vascepa arm? Guess what, both arms dieted equally. The only difference was 1 arm getting Vascepa & 1 arm getting a placebo. You're welcome. (Twitter) - Dec 2, 2022
- ||| icosapent ethyl / Generic mfg.
Clinical, Reimbursement: Well, as a pharmacist you should care about your patients and giving them a drug for an indication that it’s not approved for doesn’t seem to be in their best interest. As said above, you know that people with insurance can get branded Vascepa for $9 a month right? (Twitter) - Dec 2, 2022
- || icosapent ethyl / Generic mfg.
Congratulations, best of luck.#Vascepa (Twitter) - Dec 1, 2022
- || icosapent ethyl / Generic mfg.
5. After all this, now you question the benefits of Vascepa? JELIS, REDUCE-IT, EVAPORATE & RESPECT-EPA weren't enough for you -- you want to spend a few more billion 💸 while the top killer in the world takes a few more million lives? ... (Twitter) - Dec 1, 2022
- |||| icosapent ethyl / Generic mfg.
Pricing, Reimbursement: ...I must have missed those biologist tests. 3. Encapsulation matters. 4. Why exaggerate on the "$400" price of Vascepa? Without any insurance, one can buy 120g on Amazon for $238.10. With insurance, many pay $9/ month. It's almost as if you have an ulterior motive. 📸👇 ... (Twitter) - Dec 1, 2022
- || icosapent ethyl / Generic mfg.
Lots of 💩 in your tweet: 1. Generic Icosapent Ethyl literally doesn't have a CVD label. Are you proposing that we ignore patents - what would that do for growth and invention of drugs? 2. Do you have any evidence that the Generic is "identical" to branded Vascepa because... (Twitter) - Dec 1, 2022